Cardiac amyloidosis, once considered a rare disease, has garnered significant attention over the last few years due to three key reasons: first, increased recognition of this disease in conjunction with various common cardiac conditions such as heart failure with preserved ejection fraction and aortic stenosis; second, due to the advent of promising new therapies for light chain disease (AL), transthyretin (ATTR) cardiomyopathy, and amyloid neuropathy; finally, the advancements in cardiac imaging including echocardiography, magnetic resonance imaging, and nuclear cardiac scintigraphy aid in non-biopsy diagnosis of ATTR cardiac amyloidosis. The hereditary forms of ATTR have further come into importance with the availability of genetic testing and increased prevalence of certain mutations in African Americans. Recognition of non-cardiac clues to this disease has gained importance and reiterates that high clinical suspicion, detailed patient history, and examination with appropriate use of imaging are vital to confirm the diagnosis.

心脏淀粉样变性曾经被认为是一种罕见的疾病，但由于三个关键原因，在过去几年中引起了广泛关注：首先，对这种疾病与各种常见心脏疾病的认识得到提高，例如射血分数保留的心力衰竭和主动脉瓣狭窄；其次，由于轻链病（AL）、转甲状腺素蛋白（ATTR）心肌病和淀粉样神经病的新疗法的出现；最后，心脏成像的进步，包括超声心动图、磁共振成像和核心脏闪烁显像，有助于 ATTR 心脏淀粉样变性的非活检诊断。随着基因检测的可用性和非洲裔美国人某些突变的流行率增加，ATTR 的遗传形式进一步变得重要。